A New Small-Molecule Kinase Inhibitor for Airway Disease
Overview
Organization: National Heart, Lung, and Blood Institute
Start Date: 09/2019
End Date: Ongoing
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Help expand, coordinate, and optimize COPD research efforts
Collaboration: Nupeak Therapeutics, Inc.
Activity Type: Research
Activity Description
Respiratory airway diseases are one of the most common maladies of mankind and may be life-threatening in the form of asthma and chronic obstructive pulmonary disease (COPD). At present, there are no specific, effective, and safe drugs to fully correct the underlying basis for these diseases. The proposed development of a new type of drug to precisely attack the root cause of these conditions will thereby address an unmet need for a major public health problem.Audience
General Audience: Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: N/A
Setting: Workplace
Cost and Funding Sources
It was funded through the National Heart, Lung and Blood Institute and funds to be allotted to grantees.Impact Analysis
Results of their programs are in progress.Advice or Lessons Learned
In process.Contact Information
National Heart, Lung, and Blood Institute
Program Analyst
Bethesda
Maryland